Bio-Techne Corporation (TECH)

Market Cap	9.76B
Revenue (ttm)	1.14B
Net Income (ttm)	224.16M
Shares Out	157.19M
EPS (ttm)	1.37
PE Ratio	45.34
Forward PE	32.65
Dividend	$0.32 (0.52%)
Ex-Dividend Date	Feb 9, 2024

Volume	877,191
Open	62.45
Previous Close	62.21
Day's Range	61.94 - 62.96
52-Week Range	51.79 - 89.91
Beta	1.22
Analysts	Strong Buy
Price Target	85.44 (+37.54%)
Earnings Date	May 1, 2024

About TECH

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagn...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 9, 1989
• Employees: 3,050
• Stock Exchange: NASDAQ
• Ticker Symbol: TECH

Financial Performance

In 2023, Bio-Techne's revenue was $1.14 billion, an increase of 2.81% compared to the previous year's $1.11 billion. Earnings were $285.26 million, an increase of 4.86%.

Analyst Forecast

According to 10 analysts, the average rating for TECH stock is "Strong Buy." The 12-month stock price forecast is $85.44, which is an increase of 37.54% from the latest price.

Price Target

$85.44

(37.54% upside)

Analyst Consensus: Strong Buy